Eptifibatide


Concise Prescribing Info
Indications/Uses
Listed in Dosage.
Dosage/Direction for Use
Adult : IV Unstable angina Initial:180 mcg/kg, followed by 2 mcg/kg/min via IV infusion for up to 72 hr. Continue infusion for 18-24 hr after (PCI) procedure, up to total max duration of 96 hours of therapy. Angioplasty Initial: 180 mcg/kg immediately pre-op, followed by 2 mcg/kg/min. A 2nd dose of 180 mcg/kg should be given 10 mins later. Continue infusion until discharge or up to 18-24 hr. Min treatment duration: 12 hr.
Dosage Details
Intravenous
Unstable angina
Adult: Initially, 180 mcg/kg via IV inj, followed by 2 mcg/kg per minute via IV infusion for up to 72 hr. Continue infusion for 18-24 hr after percutaneous coronary intervention (PCI) procedure, up to total max duration of 96 hours of therapy.

Intravenous
Angioplasty
Adult: Initially, 180 mcg/kg via IV inj, to be given immediately before procedure, followed by 2 mcg/kg/minute via IV infusion. A second dose of 180 mcg/kg via IV inj should be given 10 minutes after the 1st dose. Continue infusion until hospital discharge or for up to 18-24 hr (minimum treatment duration: 12 hr).
Renal Impairment
Intravenous:
Angioplasty: Dose reduction may be needed. See Lit.
CrCl Dosage
<30 Contra-indicated.
Unstable angina: Dose reduction may be needed. See Lit.
CrCl Dosage
<30 Contraindicated.
Contraindications
Active bleeding, increased risk of haemorrhage including hemorrhagic disorders, cerebrovascular disorders, history of stroke, uncontrolled hypertension, severe trauma, severe renal impairment, recent major surgery. Lactation.
Special Precautions
Discontinue in case of serious uncontrolled bleeding, or if emergency surgery or thrombolytic therapy is required. Hepatic impairment, platelet counts <100,000 mm3; hemorrhagic retinopathy, drugs affecting haemostasis. Check aPTT or ACT prior to sheath removal. Severe renal impairment, vasculitis, haemorrhagic retinopathy, acute pericarditis or aortic dissection. Pregnancy.
Adverse Reactions
Bleeding, hypotension; localised Injection site reaction; thrombocytopaenia; back pain; anaphylaxis; GI, intracranial or pulmonary haemorrhage.
IV/Parenteral: B
Drug Interactions
Increased risk of bleeding w/ heparin, other anticoagulants, antiplatelet & thrombolytic agents.
Action
Description: Eptifibatide is a cyclic heptapeptide which blocks the platelet glycoprotein IIb/IIIa receptor thus preventing platelet aggregation and thrombosis. [PubMedID: 21211597]
Onset: Within 1 hr.
Disclaimer: This information is independently developed by MIMS based on Eptifibatide from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in